The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their ...

The Big Three PBMs have largely criticized the FTC report. A spokesperson for CVS Health argued that the FTC has drawn broad conclusions from “cherry-picked” specialty generic outliers in both ...

The FTC prioritized testimony from drugmakers and pharmacies, industries that benefit from weakening PBMs, said David Whitrap, vice president of external affairs at CVS Health. Need a break?

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

The FTC report showed that from 2017 to 2022, the three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

CVS Health, UnitedHealth Group and Cigna share prices dipped midday after the FTC released its report, but each company rebounded and was up slightly when the New York Stock Exchange closed Tuesday.

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group ... bringing in more than $7.3 billion in “excess” revenue over six years, the Federal Trade Commission said in a report on ...